Xuanzhu Biopharmaceutical, which is being spun off from China's Sihuan Pharmaceutical, soared 158% in Hong Kong grey market.
Last year, the company expanded its net loss by 85.1 percent to 556.4 million yuan (HK$608.3 million), while its revenue surged 1036.7 times to 30.1 million yuan from its core product KBP-3571 for digestive diseases during the period.